WO1999033481A3 - Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia - Google Patents

Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia Download PDF

Info

Publication number
WO1999033481A3
WO1999033481A3 PCT/EP1998/008532 EP9808532W WO9933481A3 WO 1999033481 A3 WO1999033481 A3 WO 1999033481A3 EP 9808532 W EP9808532 W EP 9808532W WO 9933481 A3 WO9933481 A3 WO 9933481A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
useful
treatment
administration
igf
Prior art date
Application number
PCT/EP1998/008532
Other languages
French (fr)
Other versions
WO1999033481A2 (en
Inventor
Aleman Ignacio Torres
Garcia Ana Ma Fernandez
Original Assignee
Applied Research Systems
Aleman Ignacio Torres
Garcia Ana Ma Fernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Aleman Ignacio Torres, Garcia Ana Ma Fernandez filed Critical Applied Research Systems
Priority to EP98966697A priority Critical patent/EP1039924A2/en
Priority to AU24182/99A priority patent/AU2418299A/en
Publication of WO1999033481A2 publication Critical patent/WO1999033481A2/en
Publication of WO1999033481A3 publication Critical patent/WO1999033481A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)

Abstract

Process using the growth factor IGF-I in the manufacture of compositions that are useful for the treatement of cerebellar ataxia. The invention which is claimed is a treatment for curing experimental ataxia which, because of the characteristics of the animal model used, may turn out to be useful in human beings. Ataxia is a neurological deficit for which there is no cure at present. The application of the IGF-I composition is by peripheral administration, which eliminates all the complications derived from the intracerebral administration which has been carried out until now for growth factors in the treatment of brain diseases. The effects obtained from the administration of IGF-I can also be achieved by the administration of compositions that increase the circulating levels thereof, for example compositions containing GHRH and/or GH.
PCT/EP1998/008532 1997-12-26 1998-12-22 Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia WO1999033481A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP98966697A EP1039924A2 (en) 1997-12-26 1998-12-22 Process using the growth factor igf-1 in the manufacture of compositions that are useful in the treatment of cerebellar ataxia
AU24182/99A AU2418299A (en) 1997-12-26 1998-12-22 Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES9702702 1997-12-26
ES9702702A ES2146530B1 (en) 1997-12-26 1997-12-26 USE OF THE IGF-I GROWTH FACTOR IN THE MANUFACTURE OF USEFUL COMPOSITIONS IN THE TREATMENT OF CEREBELAR ATAXY.

Publications (2)

Publication Number Publication Date
WO1999033481A2 WO1999033481A2 (en) 1999-07-08
WO1999033481A3 true WO1999033481A3 (en) 1999-09-10

Family

ID=8301638

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/008532 WO1999033481A2 (en) 1997-12-26 1998-12-22 Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia

Country Status (6)

Country Link
EP (1) EP1039924A2 (en)
AR (1) AR014196A1 (en)
AU (1) AU2418299A (en)
ES (1) ES2146530B1 (en)
WO (1) WO1999033481A2 (en)
ZA (1) ZA9811896B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000013650A2 (en) 1998-09-03 2000-03-16 Neuronz Limited Neuroprotection
ES2207387B1 (en) * 2002-02-28 2005-07-16 Consejo Sup. Investig. Cientificas CHEMICAL COMPOSITION OF IGF-I FOR THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747825A (en) * 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5492891A (en) * 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
US5633228A (en) * 1992-06-12 1997-05-27 Cephalon, Inc., Prevention and treatment of peripheral neuropathy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747825A (en) * 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5492891A (en) * 1991-09-05 1996-02-20 Novo Nordisk A/S Method for treatment of patients with chronic liver disease
US5633228A (en) * 1992-06-12 1997-05-27 Cephalon, Inc., Prevention and treatment of peripheral neuropathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ A M ET AL: "Insulin-like growth factor I restores motor coordination in a rat model o cerebellar ataxia.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 FEB 3) 95 (3) 1253-8, XP002102483 *
FERNANDEZ, A. M. ET AL: "Insulin - like growth factor modulates functional recovery in a rat model of cerebellar ataxia.", MEETING INFO.: 27TH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE NEW ORLEANS, LOUISIANA, USA OCTOBER 25-30, 1997 *
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 23, no. 1-2, 1997, pages 1451, XP002102591 *

Also Published As

Publication number Publication date
ZA9811896B (en) 1999-06-28
ES2146530A1 (en) 2000-08-01
AU2418299A (en) 1999-07-19
AR014196A1 (en) 2001-02-07
ES2146530B1 (en) 2001-04-16
WO1999033481A2 (en) 1999-07-08
EP1039924A2 (en) 2000-10-04

Similar Documents

Publication Publication Date Title
PL342078A1 (en) Inhibition of raf kinase using symmetrical and dissymmetrical substituted dimethylureas
DE69733132D1 (en) USE OF ANTIOXIDANTS FOR THE TREATMENT OF CHOLESTATIVE LIVER DISEASES
WO2001049281A3 (en) POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES
ATE256475T1 (en) USE OF FOLLISTATIN IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF MUSCLE DISEASES
DE69120107D1 (en) Basis or auxiliary material for external use as well as compositions containing this or these for external use on a human being or animal
ATE209492T1 (en) USE OF 1,2,4-TRIAZOLO(1,5-C)PYRIMIDINE HETEROCYCLIC ANALOGUE FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF CEREBROVASCULAR DISORDERS
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
HUP0203198A2 (en) Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
AU4835693A (en) Pharmaceutical composition comprising phosphatase or a derivative thereof
WO1993005751A3 (en) Osteogenic proteins in the treatment of bone deseases
PT76502A (en) Process for the preparation of n-glycosylated carboxamide derivatives with s stimulating effect of the body's inherent defences and their application for the preparation of pharmaceutical compositions having a stimulating effect of body's inherent defences
AU1843200A (en) Animal model for psoriasis for the prevention and treatment of psoriasis in humans
DE69521536T2 (en) Compositions containing G-CSF and a TNF binding protein
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
WO1998025573A3 (en) The use of celastrol to treat alzheimer's disease
IL141325A0 (en) Tan-1057 derivatives
WO1999033481A3 (en) Process using the growth factor igf-i in the manufacture of compositions that are useful in the treatment of cerebellar ataxia
DE69007065T2 (en) Use of diadenosine 5 ', 5' '' - p1, p4-tetraphosphate for the manufacture of a medicament for the treatment of heart diseases.
AU634003B2 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
EP0588477A3 (en) Medicinal composition comprising tcf-ii
US5547995B1 (en) Use of selegiline in veterinary medicine
DE69133074D1 (en) Agent for treating bone diseases containing a basic fibroblast growth factor
DE69424415D1 (en) USE OF EFAROXAN AND DERIVATIVES FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING PARKINSON'S DISEASE
DE69610045D1 (en) Use of a raw plant extract for the manufacture of a medicament for the treatment of HIV infections
EP0049538A3 (en) Use of thioureum derivatives as medicaments in the treatment of lipoid metabolism diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1998966697

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998966697

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1998966697

Country of ref document: EP